目的 对比格列本脲和胰岛素在妊娠期糖尿病孕妇中的应用效果.方法 选取本院2015年9月~2017年3月收治的68例妊娠期糖尿病孕妇随机纳入对照组(胰岛素)和观察组(格列本脲)中,每组34例,比较2组治疗效果及不良妊娠结局的情况.结果 2组治疗后空腹血糖(FBG)、餐后2 h血糖(2 h PG)和糖化血红蛋白(HbA1c)水平均显著下降(P<0.05),治疗后组间比较差异无统计学意义.观察组巨大儿、胎儿窒息、和新生儿低血糖发生率分别为17.65%、23.53%、20.59%,均显著高于对照组(P<0.05).结论 对妊娠期糖尿病孕妇给予格列本脲和胰岛素均可有效提升血糖控制效果,但胰岛素治疗能显著改善母婴结局,在知情同意下,部份GDM孕妇可慎用口服的降糖药物.
Comparison between glibenclamide and insulin in the treatment of gestational diabetes mellitus
Objective To analyze and compare the application results of glibenclamide and insulin in treating gestational diabetes mellitus (GDM). Methods The subjects of this study were selected from 68 cases of pregnant women with GDM admitted in our hospital from September 2015 to March 2017. They were randomly divided into the control group (insulin) and the observation group (glibenclamide), each with 34 cases. The clinical efficacy and adverse pregnancy outcomes were compared between the two groups. Results The fasting blood-glucose (FBG), 2 h postprandial plasma glucose (2 h PG), and glycosylated hemoglobin (HbA1c) levels of both groups after treatment decreased significantly (P<0.05), but there was no big difference in the above indexes between the two groups after treatment. The incidence of fetal macrosomia, fetal asphyxia and neonatal hypoglycemia in the observation group was 17.65%, 23.53% and 20.59% respectively, much higher than that in the control group (P<0.05). Conclusion In treating GDM, both glibenclamide and insulin are effective in enabling better blood-glucose control, but insulin has an advantage over the other in improving pregnancy outcomes. With the informed consent of some GDM patients, oral hypoglycemic agents can be used with caution.
NETL
NSTL
万方数据
维普
